Effect of Antidepressants on White Matter Structure

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Kiungo kimehifadhiwa kwenye clipboard

Hali

Wadhamini

Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine

Washirika

Pfizer

JARIBIO LA KLINIKI: NCT01492621

BioSeek: nct01492621

Maneno muhimu

Kikemikali

Subjects with major depression will be evaluated and intensively characterized through questionnaires, computerized cognitive evaluation and laboratory investigations. Magnetic resonance imaging will be used to document baseline white matter structure. subjects will then receive desvenlafaxine which will be adjusted as clinically indicated. After 16 weeks the evaluations will be repeated.

Maelezo

40 subjects will be included in the study. Diagnosis will be confirmed by MINI. Participants will be characterised using questionnaires, pain threshold, cognition, facial expression recording and MRI. Desvenlafaxine will be initiated at 50mg AM. At week 8 Desvenlafaxine may be increased to 100mg as clinically indicated. Measures will be repeated at the end of the study.

Tarehe

Imethibitishwa Mwisho:	11/30/2011
Iliyowasilishwa Kwanza:	12/11/2011
Uandikishaji uliokadiriwa Uliwasilishwa:	12/13/2011
Iliyotumwa Kwanza:	12/14/2011
Sasisho la Mwisho Liliwasilishwa:	12/13/2011
Sasisho la Mwisho Lilichapishwa:	12/14/2011
Tarehe halisi ya kuanza kwa masomo:	10/31/2011
Tarehe ya Kukamilisha Msingi iliyokadiriwa:	08/31/2013
Tarehe ya Kukamilisha Utafiti:	10/31/2013

Hali au ugonjwa

Major Depression

Uingiliaji / matibabu

Drug: Desvenlafaxine

Awamu

Awamu 4

Vigezo vya Kustahiki

Zama zinazostahiki Kujifunza	18 Years Kwa 18 Years
Jinsia Inastahiki Kujifunza	All
Hupokea Wajitolea wa Afya	Ndio
Vigezo	Inclusion Criteria: - Major depression - Age 18 to 55 - Hamilton grater or equal to 20 Exclusion Criteria: - Major neurologic disorder - Major cardiovascular disorder - Unstable medical condition - Significant psychiatric co-morbidity - Current substance dependance - Pregnancy or lactation -Treatment resistance as defined by nonresponse to 2 or more antidepressant treatments (adequate dose and duration) -

Matokeo

Hatua za Matokeo ya Msingi

1. Anisotropy [16 weeks]

Degree of anisotropy will be measured at baseline and 16 weeks and correlated to remission status

Hatua za Matokeo ya Sekondari

1. cognitive measures [16 weeks]

cognitive deficits will be measured at baseline and 16 weeks and correlated to anisotropy using computerized neuropsychological testing of memory, speed and executive function.

2. Pain threshold [16 weeks]

Pain threshold will be measured at basline and 16 weeks and correlated to inflammatory markers and anisotropy